Biological Therapy With Combination Chemotherapy in Patients With Colorectal Cancer

Overview

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Combining chemotherapy with biological therapy may kill more tumor cells. PURPOSE: Randomized phase III trial to compare the effectiveness of treatment using levamisole with treatment using interferon alfa and combination chemotherapy consisting of fluorouracil and leucovorin in patients with stage II or stage III colorectal cancer.

Full Title of Study: “Adjuvant Chemoimmunotherapy for Colorectal Cancer”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Primary Purpose: Treatment

Detailed Description

OBJECTIVES: – Assess the efficacy of the addition of levamisole or alfa interferon to fluorouracil and leucovorin calcium (folinic acid) as an adjuvant treatment of intraperitoneal colorectal cancer. OUTLINE: This is a three arm study. Patients are randomized to receive either levamisole, alfa interferon, or no treatment. – Arm I: Patients receive levamisole PO for 3 days every 2 weeks for 6 months before and after surgery. Fluorouracil IV bolus and leucovorin calcium (folinic acid) IV over 1 hour are administered on days 1-5 every 4 weeks for 6 cycles after surgery. – Arm II: Patients receive alfa interferon-2a SC on 3 alternate days for a week before surgery and for 6 months after surgery. Fluorouracil IV bolus and folinic acid IV over 1 hour are administered on days 1-5 every 4 weeks for 6 cycles after surgery. – Arm III: Patients undergo surgery followed by fluorouracil IV bolus and folinic acid IV over 1 hour on days 1-5 every 4 weeks for 6 cycles. Patients are followed every 3 months for 2 years, then every 6 months. PROJECTED ACCRUAL: 350 patients per arm will be accrued for a total of 1,050 patients.

Interventions

  • Biological: recombinant interferon alfa
  • Drug: fluorouracil
  • Drug: leucovorin calcium
  • Drug: levamisole hydrochloride

Participating in This Clinical Trial

DISEASE CHARACTERISTICS:

  • Histologically confirmed stage T3-T4 N0 or T1-T4 N1-3 colorectal cancer – No evidence of residual disease after surgery – Tumor located above peritoneal reflection – No distant metastases PATIENT CHARACTERISTICS: Age: – 75 and under Performance status: – WHO 0-1 Life expectancy: – Not specified Hematopoietic: – WBC at least 3500/mm3 – Platelet count at least 100,000/mm3 Hepatic: – Bilirubin no greater than 2.0 mg/dL – SGPT less than 2 times upper limit of normal Renal: – Creatinine no greater than 2.0 mg/dL Cardiovascular: – No serious cardiac ischemia Other: – Adequate metabolic functions – No prior neoplasm – No prior/concurrent illness – No insulin-dependent diabetes PRIOR CONCURRENT THERAPY: Biologic therapy – No prior immunotherapy for the current cancer Chemotherapy – No prior chemotherapy for the current cancer Endocrine therapy – Not specified Radiotherapy – No prior radiotherapy for the current cancer Surgery – Not specified

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 75 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • European Institute of Oncology
  • Overall Official(s)
    • Francesco Tonelli, MD, Study Chair, Universita Degli Studi di Florence – Policlinico di Careggi

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.